Tag: Medical

Cindy McCain suffers a mild stroke and will take leave from World Food Program while recovering

[ad_1]

Cindy McCain, the widow of Sen. John McCain and head of the U.N. World Food Program, suffered a mild stroke this week and is said to be recovering “well,” according to a press release Thursday from the humanitarian organization. The statement said McCain, 71, is expected to make a “full recovery” and will be traveling from Rome, where the WFP is based, to Arizona to focus on her recuperation. She will return to her post after her doctors have cleared her in four to six weeks. “I want to thank the medical staff in Italy for the excellent treatment I received,” said McCain. “My recovery is progressing well thanks to their outstanding care.”McCain was appointed in March 2023 to lead the world’s largest humanitarian organization after serving as U.S. ambassador to the U.N. agencies for food and agriculture under former President Joe Biden. McCain broke with Republicans when she endorsed Biden for president in 2020, making her a key surrogate for the Democrat after now-President Donald Trump spent years criticizing her husband and his military service. She has since become the face of the World Food Program, one of the few U.N. agencies that has received bipartisan support for its efforts to help nearly 150 million people confronting conflicts, disasters, and impacts of climate change this year. McCain and the WFP have been in the spotlight as the agency has sought to respond to the humanitarian crises caused by the ongoing conflict between Russia and Ukraine and Israel’s offensive inside the Gaza Strip. In late August, after visiting Gaza, McCain told The Associated Press it was “very evident” that there isn’t enough food in the Palestinian territory. She said she had spoken with Israeli Prime Minister Benjamin Netanyahu about the urgent need for more aid.Her comments came a week after the world’s leading authority on food crises said the Gaza Strip’s largest city is gripped by famine, and that it was likely to spread across the territory without a ceasefire and an end to restrictions on humanitarian aid.”I personally met mothers and children who were starving in Gaza,” she said. “It is real and it is happening now,”An advocate for children, McCain has served on the board of directors for Operation Smile, a nonprofit organization dedicated to addressing facial deformities for children around the world, visiting India, Morocco, and Vietnam, the joint announcement said.McCain succeeded David Beasley, a former South Carolina governor who had led WFP through challenging times, including the COVID-19 pandemic and the global food crisis sparked by Russia’s invasion of Ukraine. Beasley was at the helm when the World Food Program was awarded the Nobel Peace Prize in 2020, in part for being “a driving force in efforts to prevent the use of hunger as a weapon of war and conflict.”Carl Skau, the deputy executive director of WFP, is expected to oversee the organization’s day-to-day operations until McCain’s return. In the statement Thursday, McCain said she has “full confidence” in her leadership team’s ability” to stay laser-focused on delivering urgently needed food assistance to the more than 100 million people WFP is working to serve across 87 countries.”She added, “The fight against hunger has never been more critical, and I am incredibly proud of the work our teams do every day. I look forward to being back in the field soon — alongside WFP teams — pushing back against famine and supporting communities in need.”

NEW YORK —

Cindy McCain, the widow of Sen. John McCain and head of the U.N. World Food Program, suffered a mild stroke this week and is said to be recovering “well,” according to a press release Thursday from the humanitarian organization.

The statement said McCain, 71, is expected to make a “full recovery” and will be traveling from Rome, where the WFP is based, to Arizona to focus on her recuperation. She will return to her post after her doctors have cleared her in four to six weeks.

“I want to thank the medical staff in Italy for the excellent treatment I received,” said McCain. “My recovery is progressing well thanks to their outstanding care.”

McCain was appointed in March 2023 to lead the world’s largest humanitarian organization after serving as U.S. ambassador to the U.N. agencies for food and agriculture under former President Joe Biden. McCain broke with Republicans when she endorsed Biden for president in 2020, making her a key surrogate for the Democrat after now-President Donald Trump spent years criticizing her husband and his military service.

She has since become the face of the World Food Program, one of the few U.N. agencies that has received bipartisan support for its efforts to help nearly 150 million people confronting conflicts, disasters, and impacts of climate change this year. McCain and the WFP have been in the spotlight as the agency has sought to respond to the humanitarian crises caused by the ongoing conflict between Russia and Ukraine and Israel’s offensive inside the Gaza Strip.

In late August, after visiting Gaza, McCain told The Associated Press it was “very evident” that there isn’t enough food in the Palestinian territory. She said she had spoken with Israeli Prime Minister Benjamin Netanyahu about the urgent need for more aid.

Her comments came a week after the world’s leading authority on food crises said the Gaza Strip’s largest city is gripped by famine, and that it was likely to spread across the territory without a ceasefire and an end to restrictions on humanitarian aid.

“I personally met mothers and children who were starving in Gaza,” she said. “It is real and it is happening now,”

An advocate for children, McCain has served on the board of directors for Operation Smile, a nonprofit organization dedicated to addressing facial deformities for children around the world, visiting India, Morocco, and Vietnam, the joint announcement said.

McCain succeeded David Beasley, a former South Carolina governor who had led WFP through challenging times, including the COVID-19 pandemic and the global food crisis sparked by Russia’s invasion of Ukraine. Beasley was at the helm when the World Food Program was awarded the Nobel Peace Prize in 2020, in part for being “a driving force in efforts to prevent the use of hunger as a weapon of war and conflict.”

Carl Skau, the deputy executive director of WFP, is expected to oversee the organization’s day-to-day operations until McCain’s return.

In the statement Thursday, McCain said she has “full confidence” in her leadership team’s ability” to stay laser-focused on delivering urgently needed food assistance to the more than 100 million people WFP is working to serve across 87 countries.”

She added, “The fight against hunger has never been more critical, and I am incredibly proud of the work our teams do every day. I look forward to being back in the field soon — alongside WFP teams — pushing back against famine and supporting communities in need.”

[ad_2]

Source link

October 9, 2025
This health study has been collecting research samples for 50 years — Trump cut their funding

[ad_1]

EXPLAINS. WE’VE COLLECTED BLOOD SAMPLES, URINE SAMPLES, TOENAIL SAMPLES, AND WE’VE COLLECTED MANY OF THESE SAMPLES REPEATEDLY OVER TIME. THE NUMBER CATALOGED HERE IS IN THE MILLIONS SINCE 1976, MORE THAN 280,000 NURSES OF DIFFERENT AGES AND BACKGROUNDS DONATING THEIR OWN BIOLOGICAL SPECIMENS. THEN RECORDING DETAILED INFORMATION ABOUT THEIR HEALTH, LIFESTYLE AND MEDICATIONS FOR RESEARCHERS LIKE DOCTOR WALTER WILLETT. WE HAVE DOZENS OF BIG NITROGEN FREEZERS THAT ALMOST AS TALL AS I AM, LOADED WITH THOUSANDS OF SAMPLES, AND THAT TAKES ACTUALLY ABOUT $300,000 A YEAR JUST TO PROVIDE THE LIQUID NITROGEN TO KEEP THOSE SAMPLES COLD. BUT THEN LAST SPRING, THE FUNDING STOPPED. ESSENTIALLY, THE FEDERAL GOVERNMENT, TRUMP DECIDED TO ATTACK HARVARD BASICALLY ON THE BASIS OF BEING ANTI-SEMITIC, TERMINATED ALL RESEARCH, ALL FUNDING TO HARVARD. AND THAT INCLUDED OUR STUDIES. SINCE THEN, THIS SMALL TEAM HAS BEEN SCRAMBLING FOR NEW SOURCES OF SUPPORT JUST TO KEEP THESE FREEZERS FROZEN. REALLY? REMARKABLY, A NUMBER OF OUR PARTICIPANTS THEMSELVES HAVE SENT CHECKS. I THINK THEY UNDERSTAND THIS IS A GENERATIONAL TRANSFER OF KNOWLEDGE AND INFORMATION THAT CAN HELP THEIR KIDS, THEIR GRANDCHILDREN, AND EVERYBODY AROUND THE WORLD. IN THE PAST YEAR ALONE, RESEARCHERS HAVE USED THIS DATA TO TEST THEORIES ABOUT PARKINSON’S DISEASE, TYPE TWO DIABETES, BREAST CANCER, AND DEMENTIA. SOON, IT WILL BE HOW PEOPLE CAN LIVE TO 100 WITH GOOD PHYSICAL AND MENTAL HEALTH. PARTICIPANTS ARE REACHING THAT PERIOD OF THEIR LIFE AND WILL HAVE THE BEST INFORMATION ANYWHERE ON THAT, BECAUSE WE KNOW WHAT THEY’VE BEEN EATING, WHAT THEY’VE BEEN DOING AND WHAT MEDICINES THEY’VE BEEN TAKING OVER THE LAST 50 YEARS. REPORTER BUT FOR NOW, THE ONLY QUESTION THAT RESEARCHERS WANT ANSWERED CAN THIS COLLECTION STAY COLD AND ACCESSIBLE FOR ANOTHER 50 YEARS? I REGARD MYSELF AS SORT OF A CUSTODIAN. I THINK THE DATA THAT WE’RE PROVIDING REALLY DOES HELP EVERYBODY, WHETHER YOU’RE LIVING IN A RED STATE OR A BLUE STATE, BUT ALL OF A SUDDEN IT’S BECOME DIVISIVE. FOR NOW, THE LAB IS OPTIMISTIC IT CAN KEEP THE FREEZERS ON THROUGH THE END OF THE YEAR. IT’S ALSO CURRENTLY RECRUITING A THIRD COHORT OF NURSES TO JOIN THE STUDY. BUT IF FEDERAL FUNDING IS NOT RESTORED OR THERE’S NO NEW SOURCE OF MONEY, THE LAB AND ALL OF ITS DATA WILL LIKELY DISA

After funding halt, Harvard nurses health study scrambles to save 50 years of samples

Updated: 9:41 AM EDT Oct 4, 2025

Editorial Standards ⓘ

The key to living a long and happy life hasn’t been found yet.But some researchers believe it could be hiding inside the Harvard Chan School of Public Health.See the story in the video aboveThat’s where nearly 50 years of data from the Nurses’ Health Study is stored.”We’ve collected blood samples, urine samples, toenail samples,” said Dr. Walter Willett, a professor of epidemiology and nutrition. “And we’ve collected many of these samples repeatedly over time.”The number catalogued at the school’s biorepository is in the millions.Since 1976, more than 280,000 nurses of different ages and backgrounds have donated their own biological specimens and provided detailed information about their health, lifestyle, and medications for researchers like Willett to study.”We have dozens of big nitrogen freezers that are almost as tall as I am,” Willett said. “It takes about $300,000 a year just to provide liquid nitrogen to keep those samples cold.”But then last spring, the funding stopped.”Essentially, the federal government — Trump — decided to attack Harvard,” Willett said. “And basically, on the basis of being antisemitic, (it) terminated all research, all funding to Harvard, and that included our studies.”Since then, a small team has been scrambling for new sources of support, just to keep these freezers frozen.”Really remarkably, a number of our participants themselves have sent checks,” Willett said. “I think they understand this is a generational transfer of knowledge and information that can help their kids, their grandchildren, and everybody around the world.”In the past year alone, researchers have used the collection to test theories about Parkinson’s disease, Type 2 diabetes, breast cancer and dementia.Soon, they hope to discover how to live to 100 with good physical and mental health.”We’re just at a point where some of our participants are reaching that period of their life,” Willett said. “We’ll have the best information anywhere on that because we know what they’ve been eating, what they’ve been doing, and what medicines they’ve been taking over the last 50 years.”But for now, the only question that researchers want answered is whether this collection can stay cold — and accessible — for another 50 years.”I regard myself as sort of a custodian,” Willett said. “The data that we’re providing really does help everybody, whether you’re living in a red state or a blue state, but all of a sudden, it’s become divisive.”

The key to living a long and happy life hasn’t been found yet.

But some researchers believe it could be hiding inside the Harvard Chan School of Public Health.

See the story in the video above

That’s where nearly 50 years of data from the Nurses’ Health Study is stored.

“We’ve collected blood samples, urine samples, toenail samples,” said Dr. Walter Willett, a professor of epidemiology and nutrition. “And we’ve collected many of these samples repeatedly over time.”

The number catalogued at the school’s biorepository is in the millions.

Since 1976, more than 280,000 nurses of different ages and backgrounds have donated their own biological specimens and provided detailed information about their health, lifestyle, and medications for researchers like Willett to study.

“We have dozens of big nitrogen freezers that are almost as tall as I am,” Willett said. “It takes about $300,000 a year just to provide liquid nitrogen to keep those samples cold.”
But then last spring, the funding stopped.

“Essentially, the federal government — Trump — decided to attack Harvard,” Willett said. “And basically, on the basis of being antisemitic, (it) terminated all research, all funding to Harvard, and that included our studies.”

Since then, a small team has been scrambling for new sources of support, just to keep these freezers frozen.

“Really remarkably, a number of our participants themselves have sent checks,” Willett said. “I think they understand this is a generational transfer of knowledge and information that can help their kids, their grandchildren, and everybody around the world.”

In the past year alone, researchers have used the collection to test theories about Parkinson’s disease, Type 2 diabetes, breast cancer and dementia.

Soon, they hope to discover how to live to 100 with good physical and mental health.

“We’re just at a point where some of our participants are reaching that period of their life,” Willett said. “We’ll have the best information anywhere on that because we know what they’ve been eating, what they’ve been doing, and what medicines they’ve been taking over the last 50 years.”

But for now, the only question that researchers want answered is whether this collection can stay cold — and accessible — for another 50 years.

“I regard myself as sort of a custodian,” Willett said. “The data that we’re providing really does help everybody, whether you’re living in a red state or a blue state, but all of a sudden, it’s become divisive.”

[ad_2]

Source link

October 4, 2025
Novo Nordisk A/S $NVO Shares Sold by HB Wealth Management LLC

[ad_1]

HB Wealth Management LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 10.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,915 shares of the company’s stock after selling 3,537 shares during the quarter. HB Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,134,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in NVO. First Hawaiian Bank increased its holdings in Novo Nordisk A/S by 0.6% in the 1st quarter. First Hawaiian Bank now owns 22,401 shares of the company’s stock valued at $1,556,000 after purchasing an additional 142 shares during the last quarter. Anchor Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 1.1% during the first quarter. Anchor Investment Management LLC now owns 13,597 shares of the company’s stock worth $944,000 after buying an additional 150 shares during the period. Xponance Inc. grew its stake in shares of Novo Nordisk A/S by 5.0% in the first quarter. Xponance Inc. now owns 3,314 shares of the company’s stock valued at $230,000 after buying an additional 158 shares in the last quarter. Foster Dykema Cabot & Partners LLC grew its stake in shares of Novo Nordisk A/S by 3.8% in the first quarter. Foster Dykema Cabot & Partners LLC now owns 4,526 shares of the company’s stock valued at $319,000 after buying an additional 166 shares in the last quarter. Finally, Beacon Financial Group raised its holdings in shares of Novo Nordisk A/S by 6.5% in the 1st quarter. Beacon Financial Group now owns 2,884 shares of the company’s stock valued at $200,000 after buying an additional 177 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Dbs Bank upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. BNP Paribas Exane raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price objective for the company in a research note on Wednesday, August 13th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Monday. TD Cowen reduced their target price on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, August 19th. Finally, Morgan Stanley downgraded shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their price target for the stock from $59.00 to $47.00 in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.50.

Get Our Latest Report on Novo Nordisk A/S

Novo Nordisk A/S Trading Down 0.7%

NYSE NVO opened at $58.77 on Friday. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $120.56. The firm has a 50 day moving average of $55.16 and a two-hundred day moving average of $63.98. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $262.42 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 2.27 and a beta of 0.68.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio is currently 22.53%.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read More

Receive News & Ratings for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

October 3, 2025
Sound Income Strategies LLC Has $120,000 Stock Position in Bristol Myers Squibb Company $BMY

[ad_1]

Sound Income Strategies LLC lowered its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 59.1% during the second quarter, HoldingsChannel.com reports. The firm owned 2,599 shares of the biopharmaceutical company’s stock after selling 3,751 shares during the period. Sound Income Strategies LLC’s holdings in Bristol Myers Squibb were worth $120,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. New England Asset Management Inc. raised its stake in Bristol Myers Squibb by 0.8% during the 1st quarter. New England Asset Management Inc. now owns 39,476 shares of the biopharmaceutical company’s stock worth $2,408,000 after buying an additional 305 shares during the period. Commonwealth Equity Services LLC raised its stake in Bristol Myers Squibb by 1.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 1,288,407 shares of the biopharmaceutical company’s stock worth $78,580,000 after buying an additional 13,959 shares during the period. Sage Capital Advisors llc raised its stake in Bristol Myers Squibb by 60.7% during the 2nd quarter. Sage Capital Advisors llc now owns 85,234 shares of the biopharmaceutical company’s stock worth $3,946,000 after buying an additional 32,181 shares during the period. Ransom Advisory Ltd acquired a new stake in Bristol Myers Squibb during the 1st quarter worth $843,000. Finally, Avaii Wealth Management LLC raised its stake in Bristol Myers Squibb by 590.9% during the 1st quarter. Avaii Wealth Management LLC now owns 78,597 shares of the biopharmaceutical company’s stock worth $4,794,000 after buying an additional 67,221 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.07% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on BMY shares. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup lowered their target price on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a report on Friday, August 1st. Daiwa America cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Daiwa Capital Markets cut Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Tuesday, August 5th. Finally, Wall Street Zen cut Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $56.38.

Check Out Our Latest Stock Analysis on BMY

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $45.00 on Wednesday. The stock has a market capitalization of $91.59 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 2.26 and a beta of 0.35. The business has a 50-day moving average of $46.52 and a 200-day moving average of $48.86. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the company earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.5%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Bristol Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See Also

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Receive News & Ratings for Bristol Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

October 1, 2025
Arecor Therapeutics (LON:AREC) Announces Earnings Results

[ad_1]

Arecor Therapeutics (LON:AREC – Get Free Report) released its earnings results on Thursday. The company reported GBX (7) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a negative net margin of 176.89% and a negative return on equity of 118.67%.

Arecor Therapeutics Trading Up 19.7%

AREC traded up GBX 14.30 during trading on Thursday, hitting GBX 86.80. 132,247 shares of the company’s stock were exchanged, compared to its average volume of 35,933. The company has a current ratio of 1.37, a quick ratio of 6.24 and a debt-to-equity ratio of 5.51. Arecor Therapeutics has a 1 year low of GBX 35.40 and a 1 year high of GBX 100. The stock has a 50 day moving average price of GBX 63.89 and a 200 day moving average price of GBX 50.04. The firm has a market cap of £32.77 million, a P/E ratio of -280.00 and a beta of -0.18.

Arecor Therapeutics Company Profile

(Get Free Report)

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.

Further Reading

Receive News & Ratings for Arecor Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arecor Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 25, 2025
U.S. Capital Wealth Advisors LLC Boosts Stock Holdings in Merck & Co., Inc. $MRK

[ad_1]

U.S. Capital Wealth Advisors LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,420 shares of the company’s stock after purchasing an additional 2,532 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,804,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MRK. McLean Asset Management Corp lifted its position in shares of Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after buying an additional 125 shares in the last quarter. Foundation Wealth Management LLC PA raised its holdings in shares of Merck & Co., Inc. by 2.4% during the 1st quarter. Foundation Wealth Management LLC PA now owns 5,361 shares of the company’s stock worth $481,000 after acquiring an additional 127 shares in the last quarter. Saiph Capital LLC boosted its position in shares of Merck & Co., Inc. by 3.7% during the 1st quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after acquiring an additional 128 shares during the last quarter. Physician Wealth Advisors Inc. grew its holdings in shares of Merck & Co., Inc. by 2.9% in the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock valued at $363,000 after purchasing an additional 128 shares in the last quarter. Finally, N.E.W. Advisory Services LLC increased its position in Merck & Co., Inc. by 2.6% in the first quarter. N.E.W. Advisory Services LLC now owns 5,197 shares of the company’s stock worth $466,000 after purchasing an additional 130 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

MRK has been the subject of several research reports. Wells Fargo & Company lowered their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their target price for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Finally, Morgan Stanley dropped their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $106.41.

Check Out Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $79.89 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $116.26. The company has a market capitalization of $199.54 billion, a price-to-earnings ratio of 12.31, a PEG ratio of 0.83 and a beta of 0.37. The firm’s 50-day moving average is $82.69 and its 200 day moving average is $82.23.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.10. The business had revenue of $15.81 billion during the quarter, compared to analyst estimates of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 4.1%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.92%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Receive News & Ratings for Merck & Co. Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Co. Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 24, 2025
AI Medical Tools Provide Worse Treatment for Women and Underrepresented Groups

[ad_1]

Historically, most clinical trials and scientific studies have primarily focused on white men as subjects, leading to a significant underrepresentation of women and people of color in medical research. You’ll never guess what has happened as a result of feeding all of that data into AI models. It turns out, as the Financial Times calls out in a recent report, that AI tools used by doctors and medical professionals are producing worse health outcomes for the people who have historically been underrepresented and ignored.

The report points to a recent paper from researchers at the Massachusetts Institute of Technology, which found that large language models including OpenAI’s GPT-4 and Meta’s Llama 3 were “more likely to erroneously reduce care for female patients,” and that women were told more often than men “self-manage at home,” ultimately receiving less care in a clinical setting. That’s bad, obviously, but one could argue that those models are more general purpose and not designed to be use in a medical setting. Unfortunately, a healthcare-centric LLM called Palmyra-Med was also studied and suffered from some of the same biases, per the paper. A look at Google’s LLM Gemma (not its flagship Gemini) conducted by the London School of Economics similarly found the model would produce outcomes with “women’s needs downplayed” compared to men.

A previous study found that models similarly had issues with offering the same levels of compassion to people of color dealing with mental health matters as they would to their white counterparts. A paper published last year in The Lancet found that OpenAI’s GPT-4 model would regularly “stereotype certain races, ethnicities, and genders,” making diagnoses and recommendations that were more driven by demographic identifiers than by symptoms or conditions. “Assessment and plans created by the model showed significant association between demographic attributes and recommendations for more expensive procedures as well as differences in patient perception,” the paper concluded.

That creates a pretty obvious problem, especially as companies like Google, Meta, and OpenAI all race to get their tools into hospitals and medical facilities. It represents a huge and profitable market—but also one that has pretty serious consequences for misinformation. Earlier this year, Google’s healthcare AI model Med-Gemini made headlines for making up a body part. That should be pretty easy for a healthcare worker to identify as being wrong. But biases are more discreet and often unconscious. Will a doctor know enough to question if an AI model is perpetuating a longstanding medical stereotype about a person? No one should have to find that out the hard way.

[ad_2]

AJ Dellinger

Source link

September 21, 2025
276 Shares in Agilent Technologies, Inc. $A Bought by Central Pacific Bank Trust Division

[ad_1]

Central Pacific Bank Trust Division bought a new stake in Agilent Technologies, Inc. (NYSE:A – Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 276 shares of the medical research company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Agilent Technologies by 0.7% during the first quarter. Vanguard Group Inc. now owns 33,408,626 shares of the medical research company’s stock worth $3,908,141,000 after purchasing an additional 240,965 shares during the last quarter. Pictet Asset Management Holding SA raised its holdings in shares of Agilent Technologies by 2.5% during the first quarter. Pictet Asset Management Holding SA now owns 5,341,870 shares of the medical research company’s stock valued at $624,888,000 after buying an additional 128,131 shares during the last quarter. Generation Investment Management LLP raised its holdings in Agilent Technologies by 19.8% during the first quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after purchasing an additional 824,243 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Agilent Technologies by 18.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock valued at $448,748,000 after buying an additional 604,124 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Agilent Technologies by 9.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,231,981 shares of the medical research company’s stock worth $434,184,000 after purchasing an additional 283,445 shares in the last quarter.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $125.68 on Tuesday. The firm has a 50 day moving average of $119.89 and a 200-day moving average of $115.77. The stock has a market capitalization of $35.63 billion, a PE ratio of 29.50, a PEG ratio of 3.83 and a beta of 1.24. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $153.84. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53.

Agilent Technologies (NYSE:A – Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The company’s revenue was up 10.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on A shares. Evercore ISI reduced their price objective on shares of Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research note on Thursday, August 28th. Robert W. Baird increased their price target on shares of Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. TD Cowen increased their price target on shares of Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. UBS Group decreased their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research note on Thursday, May 29th. Finally, Wells Fargo & Company increased their price target on shares of Agilent Technologies from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Monday. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.08.

Check Out Our Latest Research Report on A

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,508 shares of Agilent Technologies stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer owned 37,448 shares in the company, valued at $4,397,893.12. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).

Receive News & Ratings for Agilent Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agilent Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 16, 2025
First Hawaiian Bank Buys 3,531 Shares of Pfizer Inc. $PFE

[ad_1]

First Hawaiian Bank lifted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 6.9% in the first quarter, HoldingsChannel.com reports. The fund owned 54,455 shares of the biopharmaceutical company’s stock after acquiring an additional 3,531 shares during the quarter. First Hawaiian Bank’s holdings in Pfizer were worth $1,380,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in PFE. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the 1st quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in Pfizer in the first quarter worth approximately $28,000. North Capital Inc. bought a new position in Pfizer during the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the fourth quarter worth approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $23.91 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average of $24.79 and a 200-day moving average of $24.28. The firm has a market cap of $135.94 billion, a P/E ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 EPS. Pfizer’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. HSBC cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Berenberg Bank reduced their price target on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research report on Thursday, May 29th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.12.

Read Our Latest Stock Report on PFE

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 14, 2025
Dynamic Technology Lab Private Ltd Buys 15,151 Shares of Evolus, Inc. $EOLS

[ad_1]

Dynamic Technology Lab Private Ltd increased its stake in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 80.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,037 shares of the company’s stock after acquiring an additional 15,151 shares during the quarter. Dynamic Technology Lab Private Ltd owned 0.05% of Evolus worth $410,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Millennium Management LLC increased its stake in shares of Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after acquiring an additional 23,605 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock valued at $400,000 after buying an additional 1,838 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Evolus in the 1st quarter valued at about $5,851,000. PDT Partners LLC acquired a new stake in shares of Evolus in the 1st quarter valued at about $730,000. Finally, Graham Capital Management L.P. grew its stake in shares of Evolus by 22.8% in the 1st quarter. Graham Capital Management L.P. now owns 57,694 shares of the company’s stock valued at $694,000 after buying an additional 10,731 shares during the period. Institutional investors own 90.69% of the company’s stock.

Insider Transactions at Evolus

In other Evolus news, Director Brady Stewart bought 30,000 shares of the business’s stock in a transaction dated Friday, August 15th. The shares were purchased at an average price of $6.82 per share, for a total transaction of $204,600.00. Following the purchase, the director directly owned 88,629 shares of the company’s stock, valued at approximately $604,449.78. This represents a 51.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the transaction, the chief marketing officer owned 89,949 shares in the company, valued at $675,516.99. The trade was a 5.98% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

EOLS has been the subject of several research reports. BTIG Research restated a “buy” rating and issued a $18.00 target price on shares of Evolus in a research note on Monday. HC Wainwright reduced their target price on Evolus from $27.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, August 6th. Wall Street Zen downgraded Evolus from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Finally, Needham & Company LLC restated a “hold” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.25.

Read Our Latest Stock Report on EOLS

Evolus Stock Performance

NASDAQ EOLS opened at $7.51 on Friday. Evolus, Inc. has a 1 year low of $5.71 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 1.86. The firm has a market cap of $485.75 million, a price-to-earnings ratio of -7.66 and a beta of 1.07. The company has a fifty day moving average price of $8.12 and a 200-day moving average price of $10.00.

Evolus Company Profile

(Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More

Receive News & Ratings for Evolus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evolus and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 12, 2025

Contrasting Cencora (NYSE:COR) & SBC Medical Group (NASDAQ:SBC)

[ad_1]

Cencora (NYSE:COR – Get Free Report) and SBC Medical Group (NASDAQ:SBC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Cencora and SBC Medical Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0	3	9	0	2.75
SBC Medical Group	0	0	0	0	0.00

Cencora presently has a consensus price target of $311.25, indicating a potential upside of 4.57%. Given Cencora’s stronger consensus rating and higher probable upside, equities analysts plainly believe Cencora is more favorable than SBC Medical Group.

Risk & Volatility

Cencora has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500.

Profitability

This table compares Cencora and SBC Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cencora	0.60%	267.36%	4.31%
SBC Medical Group	17.71%	20.76%	15.56%

Valuation & Earnings

This table compares Cencora and SBC Medical Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$293.96 billion	0.20	$1.51 billion	$9.72	30.62
SBC Medical Group	$205.42 million	2.52	$46.61 million	$0.32	15.59

Cencora has higher revenue and earnings than SBC Medical Group. SBC Medical Group is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

97.5% of Cencora shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 10.8% of Cencora shares are held by company insiders. Comparatively, 89.5% of SBC Medical Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cencora beats SBC Medical Group on 9 of the 14 factors compared between the two stocks.

About Cencora

(Get Free Report)

Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

About SBC Medical Group

(Get Free Report)

SBC Medical Group Holdings Incorporated, through its subsidiaries, provides services to support the operation of clinics which deliver specialized medical services in the areas of cosmetic medicine, esthetic dentistry and Androgenetic Alopecia or AGA, primarily in Japan and centered on the SBC Shonan Beauty Clinic Brand. SBC Medical Group Holdings Incorporated, formerly known as Pono Capital Two Inc., is based in TOKYO.

Receive News & Ratings for Cencora Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cencora and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 9, 2025

Mom shares video of baby eating ice cream—days later, life changes forever

[ad_1]

A mother has illustrated how quickly and completely her daughter’s life changed—just by sharing a video of her eating ice cream.

Erica Minond, 31, lives in New Jersey, and is mom to a baby boy born earlier this year, and her two-and-a-half-year old daughter, Lydia.

Minond runs TikTok account @lydia.jean.pdcd, which she uses to raise awareness of a rare disease her daughter lives with: PDCD, or Pyruvate Dehydrogenase Complex Deficiency.

As Minond explained it to Newsweek, PDCD “is a rare, life-limiting genetic disease that prevents the body from using sugar and carbohydrates for energy.”

“Normally when we eat carbs, the body turns them into fuel to power the brain and muscles. In PDCD the ‘gate’ that allows this conversion is essentially broken,” she said. “Instead of becoming energy, sugar builds up and turns into acid in the blood. At the same time, the brain and body are left starving for ‘fuel’.

“For Lydia, this means carbs are toxic.”

Lydia eating ice cream as a baby before her diagnosis.

TikTok @lydia.jean.pdcd

Since 2023, the dedicated mother has been running Lydia’s TikTok account to share her journey with PDCD, and on August 23 she shared what first appeared to be a sweet but ordinary clip of Lydia as a baby, trying her first mouthful of ice cream.

In the clip, Lydia, then aged five months, smiles at her mom with bight blue ice cream around her mouth—but Minond wrote over it: “Late night finds but it’s the only video I’ll ever have of my daughter eating ice cream because five days after this she was diagnosed with a terminal condition where her body can’t break down sugar.”

“A little over two years later and I still get upset thinking of all the foods Lydia will never be able to enjoy due to this condition,” she added in a caption.

Minond explained to Newsweek that Lydia was born “healthy,” with “no sign of anything wrong at birth or in the weeks after.”

By four months old, Lydia was not properly holding her head up by herself, and while she was diagnosed with low muscle tone, doctors suggested she would likely “catch up,” and it was not a major issue. But Minond, noticing Lydia’s pupils were two different sizes, and that she favored her right side, “had a gut feeling something was not right, despite multiple doctors’ assurance that she was fine.”

She took things into her own hands, seeking genetic testing for diseases that present similarly to cerebral palsy, and received the results when her daughter was five-and-a-half months old, changing their lives forever.

If Lydia eats carbs, her body produces lactic acid, which builds up in the blood and “can make her dangerously ill very quickly,” with symptoms including vomiting, lethargy, confusion, seizures, loss of consciousness, organ failure, and even death.

The only way to keep her daughter “safe,” Minond said, is with an extremely strict medical ketogenic diet for the entirety of her life, which doesn’t cure the disease, but slows its progression.

“For most kids, sugar is a treat, but for Lydia it could take her life. Her future is still uncertain, but every day on the medical ketogenic diet gives her more time to grow and learn.”

A ketogenic diet lacks carbohydrates—such as milk, grains, pasta and potatoes— and is instead rich in proteins and fats, typically including meats, eggs, cheese, fish and fibrous vegetables. It is difficult to follow—carbohydrates usually account for around 50 percent of the typical American diet, according to Harvard Health.

A 2017 study published in the National Library of Medicine studied the short and long-term outcomes of a ketogenic diet in PDCD found that it had a positive effect, particularly in epilepsy, ataxia, sleep disturbance, speech and language development, social functioning and frequency of hospitalizations.

She shared the video of her daughter’s first and only taste of ice cream to showcase that “my daughter will never be able to have a scoop, let alone a single bite, of ‘regular’ ice cream ever again in her life.”

Photos of Lydia, who has PDCD, now, aged two-and-a-half.

Erica Minond

But, she said, the clip exploded in popularity “for the wrong reasons.”

The video has been viewed close to 700,000 times, but some commenters chose to take that opportunity to scold Minond for giving her ice cream in the first place, which is generally not recommended until a baby is older than six months or a year.

One commenter wrote: “Yeah cause she shouldn’t have ice cream when she’s only like four months old.”

However plenty leapt to Minond’s defence, with one replying to a commenter who said Lydia was “too young for artificial sugar” by writing: “Too young for a terminal illness. But here we are.”

Minond herself replied to one commenter: “Thankfully the 3 bites of ice cream she ate didn’t cause her terminal GENETIC condition. She was born with it. The 3 bites of ice cream have not impacted her health at all. Thanks though!”

And as one commenter put it: “All these comments about her age. At least she got to try it.”

“Because her brain runs on limited energy, her development is delayed and the condition is considered terminal,” she said. “Every day is a balance of protecting her from the foods her body cannot handle while ensuring she gets the fuel she needs to live and grow.”

Now two-and-a-half years old, Lydia has recently started to walk, and has up to 20 words in her vocabulary—skills her mother describes as “miracles.”

“When we first received her diagnosis we were provided with the grim statistic that 90 percent of children diagnosed with this condition die by 4 years old, and she would likely never walk or talk.”

Since Lydia’s diagnosis, Minond has found solace in parent-led non-profit Hope for PDCD Foundation, dedicated to finding a cure for the disease and which “helps give children with PDCD, like Lydia, a chance at more time, better quality of life, and hope for the future.”

And despite her health difficulties, Minond said her daughter has grown into a “funny, curious, loving, and opinionated” little girl.

“She loves Ms. Rachel and loves to paint. She is truly such a special, happy girl.”

[ad_2]

Source link

August 30, 2025
Needham & Company LLC Boosts Veeva Systems (NYSE:VEEV) Price Target to $355.00

[ad_1]

Veeva Systems (NYSE:VEEV – Free Report) had its price target lifted by Needham & Company LLC from $300.00 to $355.00 in a research note released on Thursday morning,Benzinga reports. They currently have a buy rating on the technology company’s stock.

A number of other analysts have also recently weighed in on VEEV. KeyCorp boosted their price target on Veeva Systems from $285.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday, July 14th. Wells Fargo & Company boosted their price target on Veeva Systems from $300.00 to $326.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus boosted their price target on Veeva Systems from $272.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, May 29th. UBS Group boosted their price objective on Veeva Systems from $250.00 to $285.00 and gave the stock a “neutral” rating in a research report on Thursday, May 29th. Finally, Piper Sandler boosted their price objective on Veeva Systems from $255.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, May 29th. Sixteen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average price target of $298.68.

Check Out Our Latest Report on Veeva Systems

Veeva Systems Price Performance

Shares of NYSE:VEEV opened at $272.51 on Thursday. Veeva Systems has a fifty-two week low of $200.30 and a fifty-two week high of $296.72. The business has a 50-day moving average of $282.59 and a two-hundred day moving average of $253.79. The stock has a market capitalization of $44.53 billion, a P/E ratio of 55.96, a P/E/G ratio of 2.33 and a beta of 0.95.

Veeva Systems (NYSE:VEEV – Get Free Report) last announced its quarterly earnings results on Wednesday, May 28th. The technology company reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.23. Veeva Systems had a return on equity of 14.19% and a net margin of 27.29%.The company had revenue of $759.04 million during the quarter, compared to analysts’ expectations of $728.38 million. During the same quarter in the previous year, the firm earned $1.50 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. As a group, research analysts expect that Veeva Systems will post 4.35 EPS for the current fiscal year.

Insider Activity at Veeva Systems

In related news, SVP Jonathan Faddis sold 720 shares of the business’s stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $285.62, for a total transaction of $205,646.40. Following the transaction, the senior vice president directly owned 7,902 shares in the company, valued at $2,256,969.24. The trade was a 8.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Timothy S. Cabral sold 315 shares of the business’s stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $289.72, for a total value of $91,261.80. Following the transaction, the director owned 5,500 shares in the company, valued at $1,593,460. This represents a 5.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,378 shares of company stock worth $394,217 over the last three months. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On Veeva Systems

Hedge funds and other institutional investors have recently made changes to their positions in the business. Abound Financial LLC bought a new position in shares of Veeva Systems during the 1st quarter worth about $25,000. ORG Partners LLC bought a new position in shares of Veeva Systems during the 1st quarter worth about $26,000. Trust Co. of Toledo NA OH bought a new stake in shares of Veeva Systems in the 2nd quarter valued at approximately $29,000. Golden State Wealth Management LLC grew its stake in shares of Veeva Systems by 152.9% in the 1st quarter. Golden State Wealth Management LLC now owns 129 shares of the technology company’s stock valued at $30,000 after purchasing an additional 78 shares during the period. Finally, Wayfinding Financial LLC bought a new stake in shares of Veeva Systems in the 1st quarter valued at approximately $32,000. 88.20% of the stock is owned by institutional investors.

About Veeva Systems

(Get Free Report)

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.

Featured Articles

Receive News & Ratings for Veeva Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veeva Systems and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

August 29, 2025
Treating PTSD with Cannabis: Long-Awaited Study Gets FDA Green Light

[ad_1]

After years of delays, researchers are set to move forward on a landmark clinical trial meant to evaluate the efficacy of smoked medical marijuana in treating post-traumatic stress disorder (PTSD) in military veterans. The study is being funded with tax revenue from legal cannabis sales in Michigan.

The Multidisciplinary Association for Psychedelic Studies, or MAPS, announced this week that the U.S. Food and Drug Administration (FDA) gave approval for Phase 2 of the research, which MAPS described in a press release as “a randomized, placebo-controlled study of 320 Veterans suffering from moderate to severe PTSD who have previously used cannabis.”

The group said the study “is designed to investigate the inhalation of high THC dried cannabis flower, versus placebo cannabis, with the daily dose being self-titrated by participants.” It’s meant to reflect consumption patterns already happening across the country and study “the ‘real-world’ use of inhaled cannabis to understand its potential benefits and risks in treating PTSD.”

MAPS said the project is years in the making, noting that it faced several challenges in clearing the research with the FDA that were only recently resolved.

“After three years of negotiations with the FDA, this decision opens the door to future research into cannabis as a medical treatment, offering hope to millions,” the organization said.

“These data are critical to inform patients, medical providers, and adult-use consumers when considering cannabis in treatment plans for the management of PTSD, pain, and other serious health conditions,” the group’s press release said, “yet regulatory obstacles have historically made it difficult or impossible to conduct meaningful research on the safety and effectiveness of cannabis products typically consumed in regulated markets.”

MAPS said that over the years, it responded to five partial clinical hold letters from the FDA that halted the study’s progress.

“On August 23, 2024, MAPS responded to the FDA’s fifth clinical hold letter by submitting a Formal Dispute Resolution Request (FDRR) to resolve the continued scientific and regulatory disagreement with the Division on four key issues,” according to the organization: “1) the proposed THC dose of the cannabis flower product, 2) smoking as a delivery method, 3) vaping as a delivery method, and 4) the enrollment of cannabis naïve participants.”

After more than three years of tireless effort and five rounds of pushback from FDA, MAPS has won a Formal Dispute Resolution Request (FDRR) with the FDA’s Division of Psychiatry — the same Division that rejected Lykos’ New Drug Application for MDMA-assisted therapy for PTSD.… pic.twitter.com/sUiTjAIV9F

— MAPS (@MAPS) November 20, 2024

Sue Sisley, a psychiatrist and the principal investigator for the study, said the trial will help shed more light on the scientific legitimacy of using smoked marijuana to treat PTSD. Despite the growing use of cannabis among patients with PTSD and the condition’s inclusion in many state medical marijuana programs, she said there’s a lack of rigorous data evaluating the treatment’s efficacy.

“Within the United States, millions of Americans are smoking or vaporizing cannabis to manage or treat their symptoms,” Sisley said in a statement. “In the absence of high-quality data related to cannabis, much of the information available to patients and regulators is rooted in prohibition and focused only on potential risks, without consideration of potential benefits.”

“In my own practice, Veteran patients have shared how smoking cannabis helped them manage their PTSD symptoms more than traditional pharmaceuticals,” she continued. “Suicide among Veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for life-threatening health conditions like PTSD.”

Phase 2 of the research, Sisley said, “will generate data that doctors, like myself, can use to develop treatment plans to help people manage their PTSD symptoms.”

Allison Coker, director of cannabis research at MAPS, said the resolution with the FDA came when the agency said it would allow Phase 2 to proceed with smoked cannabis at commercially available THC levels. Vaporization remains on hold, however, until the FDA can assess the safety of any particular delivery device.

In response to the FDA’s separate concern around enrolling cannabis-naive participants in the study, MAPS updated the protocol to require that participants must have “prior experience inhaling (smoking or vaporizing) cannabis.”

FDA had also taken issue with the study’s design of allowing self-titration — meaning participants can consume as much cannabis as they choose, up to a certain amount — but MAPS refused to relent on that point.

An FDA spokesperson told the New York Times, which first reported the Phase 2 approval, that she was unable to provide details about what led to the decision but said that the agency “recognizes that there is great need for additional treatment options for mental health conditions such as PTSD.”

The study is being funded by Michigan’s Veteran Marijuana Research Grant Program, which uses state revenue from legal cannabis taxes to fund FDA-approved, nonprofit-sponsored clinical trials “researching the efficacy of marijuana in treating the medical conditions of United States armed services veterans and preventing veteran suicide.”

State officials announced $13 million in funding for the research back in 2021, part of a total $20 million grant funding round. Another $7 million that year went to Wayne State University’s Bureau of Community Action and Economic Opportunity, which partnered with researchers to study how cannabis might treat a variety of mental health disorders, including PTSD, anxiety, sleep disorders, depression, and suicidality.

In 2022, meanwhile, the Michigan Cannabis Regulatory Agency recommended that year’s $20 million go toward two universities: the University of Michigan, where researchers proposed looking at the use of CBD in pain management, and Wayne State University, which was awarded grants for two separate studies: one that billed itself as the “first randomized, controlled, large-scale clinical trial” to examine whether the use of cannabinoids could improve outcomes for veterans with PTSD who are undergoing prolonged exposure (PE) therapy and another into the effects of marijuana on “neuroinflammation and neurobiological underpinnings of suicide ideation in veterans with PTSD.”

The founder and president of MAPS, Rick Doblin, said in the group’s announcement of the newly FDA-approved trial that veterans “are in dire need of treatments that can ease their challenging symptoms of PTSD.”

“MAPS takes pride in leading the way to open new research pathways by challenging the FDA to think differently,” he said. “Our cannabis work challenges FDA’s typical approach to scheduled dosing and administration of drugs. MAPS refused to compromise the study design in order to fit into the standard box of FDA thinking in order to ensure that cannabis research reflects cannabis use.”

MAPS’s past research has included not just cannabis but also, as the group’s name suggests, psychedelics. It created a spinoff drug development company, Lykos Therapeutics (formerly MAPS Public Benefit Corporation), that sought FDA approval earlier this year of MDMA to treat PTSD.

But in August, the FDA declined to approve the MDMA-assisted therapy. Separate research, published in the Journal of Psychedelic Studies, found that while results of clinical trials have been “encouraging,” more robust research is needed before MDMA-assisted therapy (MDMA-AT) sees widespread adoption over currently available forms of treatment

Some health officials said afterward that the effort nevertheless reflected progress at the federal level.

“We all feel some type of way about the decision that came out some time ago, and that’s OK,” said Leith J. States, chief medical officer at the Office of the Assistant Secretary for Health. “It’s indicative of a fact that we’re moving forward…and we’re doing things in a way that marches us forward in an incremental way.”

Separately this month, a Drug Enforcement Administration (DEA) judge rejected a veterans group’s petition to participate in an upcoming hearing on the Biden administration’s marijuana rescheduling proposal, which the organization, the Veterans Action Council (VAC), called a “travesty of justice” that excludes key voices that would be affected by the potential policy change.

While DEA “devised a reasonably inclusive stakeholder assortment” of witnesses, VAC said it still “failed” to fulfill its mandate to allow testimony from interested parties. And the veterans organization said that’s evidenced by the fact that Mulrooney has since delayed the formal hearing proceedings until early 2025 because DEA provided insufficient information about their selected witnesses’ position on rescheduling or why they should be considered interested parties.

Meanwhile, in Congress, a new U.S. Senate bill introduced this month aims to ensure benefits for veterans exposed to potentially hazardous chemicals during the Cold War era — including psychedelics like LSD, nerve agents and mustard gas. The secret testing program, which ran from 1948 to 1975 at an Army base in Maryland, involved former Nazi scientists administering the substances to American military members.

More recently, the U.S. military has also invested millions in an effort to develop a new class of drugs that offers the same fast-acting mental health benefits as traditional psychedelics but without a psychedelic trip.

Veterans have taken a lead role in both medical marijuana legalization and the psychedelics reform movement currently unfolding at the state and federal levels. Earlier this year, for example, veterans service organizations (VSOs) pressed members of Congress to urgently pursue the potential benefits of psychedelic-assisted therapy and medical marijuana.

The requests from groups like the Iraq and Afghanistan Veterans of America, Veterans of Foreign Wars of the United States, Disabled American Veterans, and the Wounded Warrior Project came on the heels of organizations at last year’s set of annual VSO hearings criticizing the Department of Veterans Affairs (VA) for “dragging their feet” on medical marijuana research.

Led largely by Republican politicians, efforts at reform have included a GOP-sponsored psychedelics bill in Congress that focused on veterans’ access, various state-level changes, and a bevy of hearings on expanded access.

Rep. Derrick Van Orden (R-WI), who filed one congressional psychedelics bill that advanced through a committee, is also a co-sponsor of a bipartisan measure to provide funding to the Department of Defense (DOD) to conduct clinical trials into the therapeutic potential of certain psychedelics for active duty military members. That reform was signed into law by President Joe Biden under an amendment attached to the 2024 National Defense Authorization Act (NDAA).

In March, congressional appropriations leaders also unveiled a spending package that contains language providing $10 million to facilitate the psychedelics studies.

In January, the VA separately issued a request for applications to conduct in-depth research on the use of psychedelics to treat PTSD and depression. And last October, the department launched a new podcast about the future of veteran health care, with the first episode of the series focused on the healing potential of psychedelics.

At the state level, the governor of Massachusetts in August signed a military veterans-focused bill that includes provisions to create a psychedelics working group to study and make recommendations about the potential therapeutic benefits of substances like psilocybin and MDMA.

Meanwhile, in California, lawmakers in June pulled from consideration a bipartisan bill that would have authorized a pilot program to provide psilocybin treatment to military veterans and former first responders.

Correction: As the result of an editing error, an earlier version of this story attributed quotes to incorrect members of the MAPS team. Those attributions have been corrected.

Written by Ben Adlin for Marijuana Moment | Featured image by Anthony Brown/Weedmaps

[ad_2]

Marijuana Moment

Source link

December 11, 2024
Mount Yale Investment Advisors LLC Has $791,000 Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

[ad_1]

Mount Yale Investment Advisors LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 23.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,278 shares of the medical research company’s stock after selling 381 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $791,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Signature Resources Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. New Millennium Group LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $29,000. Stephens Consulting LLC boosted its holdings in shares of Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after buying an additional 29 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at $32,000. Finally, Bank & Trust Co acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,548,375.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Marc N. Casper sold 6,300 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,548,375.44. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. Barclays reduced their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday. Stephens initiated coverage on Thermo Fisher Scientific in a report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, Bernstein Bank upped their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Check Out Our Latest Stock Report on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

TMO opened at $554.38 on Friday. The firm has a market cap of $211.77 billion, a P/E ratio of 34.39, a PEG ratio of 3.75 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a fifty-two week low of $420.21 and a fifty-two week high of $627.88. The firm has a 50-day moving average of $605.12 and a 200 day moving average of $584.00.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 EPS. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Receive News & Ratings for Thermo Fisher Scientific Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Thermo Fisher Scientific and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

October 27, 2024
Positive Medical News About Marijuana And Moms

[ad_1]

Federally funded medical research reveals marijuana not tied to autism.

Drinking, smoking and consuming marijuana while pregnant is never recommended. Over the course of history, woman have consumed liquor, especially during the period when clean water was hard to find, but child mortality was high. With advances in medicine, it has been discovered some activities, like drinking and smoking cigarettes, can cause harm to the baby. No one is saying expectant women should have booze, buds, or cigarettes. But early on, when a woman doesn’t know she is expecting, she might have engaged in these habits

RELATED: Science Says Medical Marijuana Improves Quality Of Life

One of the concerns circling around cannabis is how it can affect a baby’s development. While more research needs to be done, two new studies have been published in the Journal of the American Medical Association (JAMA) which provides some good news. The first study focused on discovering if maternal cannabis use during early pregnancy associated with risk of child autism spectrum disorder (ASD).

Photo by Anastasiia Chepinska via Unsplash

This study included 178 948 mother-child combinations. The children were born between 2011 and 2019 to pregnant Kaiser Permanente Northern California members screened for prenatal cannabis use during pregnancy. Statistical analysis was conducted February 2023 to March 2024. The findings suggest maternal cannabis use during early pregnancy was not associated with child ASD, but additional research should be conducted to replicate the findings.

Another study released this week found maternal cannabis use during early pregnancy was not associated with speech and language disorders, global delay, or motor delay. The investigation into marijuana and childhood development and included 119 976 pregnancies among 106 240 unique pregnant individuals.

RELATED: Couples Using Cannabis Can Increase Intimacy

A reason for the study is with legal marijuana increased, this is increased discussion around it being a cause of developmental development among babies. But documented associations between maternal prenatal cannabis use and adverse birth outcomes, including preterm birth and low birthweight have not be in a study. There has been little research assessing the association of maternal prenatal cannabis use and childhood developmental outcomes, this study was done to provide a scientific fact around the information.

More research needs to be done, and like alcohol and cigarettes which are harmful for the body, not one is saying it is good to use why expecting, but it is good to have information grounded in facts.

[ad_2]

Amy Hansen

Source link

October 18, 2024
Fred Alger Management LLC Has $16.24 Million Stock Holdings in Nevro Corp. (NYSE:NVRO)

[ad_1]

Fred Alger Management LLC lowered its position in shares of Nevro Corp. (NYSE:NVRO – Free Report) by 7.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,928,144 shares of the medical equipment provider’s stock after selling 155,543 shares during the quarter. Fred Alger Management LLC owned about 5.25% of Nevro worth $16,235,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVRO. Charles Schwab Investment Management Inc. raised its position in shares of Nevro by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 280,528 shares of the medical equipment provider’s stock valued at $6,037,000 after buying an additional 3,860 shares in the last quarter. Norges Bank bought a new stake in shares of Nevro during the 4th quarter valued at $8,498,000. Assetmark Inc. grew its holdings in shares of Nevro by 30.4% during the 4th quarter. Assetmark Inc. now owns 3,131 shares of the medical equipment provider’s stock worth $67,000 after purchasing an additional 730 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Nevro by 69.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider’s stock worth $22,554,000 after purchasing an additional 431,136 shares during the period. Finally, Nomura Holdings Inc. raised its stake in Nevro by 28.1% in the fourth quarter. Nomura Holdings Inc. now owns 59,250 shares of the medical equipment provider’s stock valued at $1,275,000 after purchasing an additional 13,000 shares in the last quarter. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Price Performance

Nevro stock opened at $5.40 on Thursday. The company has a market capitalization of $201.31 million, a PE ratio of -2.36 and a beta of 0.94. The company has a current ratio of 4.77, a quick ratio of 3.53 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $6.64 and a two-hundred day moving average price of $9.43. Nevro Corp. has a 12 month low of $4.38 and a 12 month high of $22.64.

Nevro (NYSE:NVRO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.10. Nevro had a negative net margin of 18.17% and a negative return on equity of 24.89%. The business had revenue of $104.16 million during the quarter, compared to analyst estimates of $107.11 million. During the same quarter last year, the business earned ($0.69) EPS. The firm’s quarterly revenue was down 4.3% on a year-over-year basis. Analysts expect that Nevro Corp. will post -2.6 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NVRO. Robert W. Baird reduced their price objective on shares of Nevro from $11.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Wells Fargo & Company lowered shares of Nevro from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $13.00 to $5.50 in a research report on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Nevro from a “neutral” rating to an “underweight” rating in a research report on Wednesday, August 7th. Piper Sandler reduced their target price on Nevro from $12.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, August 7th. Finally, Truist Financial lowered their price target on Nevro from $10.00 to $5.50 and set a “hold” rating for the company in a report on Thursday, August 8th. Four analysts have rated the stock with a sell rating and eleven have issued a hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $10.63.

Check Out Our Latest Analysis on Nevro

Nevro Company Profile

(Free Report)

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.

Read More

Receive News & Ratings for Nevro Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nevro and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 26, 2024
State of New Jersey Common Pension Fund D Takes $2.21 Million Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

[ad_1]

State of New Jersey Common Pension Fund D acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 197,856 shares of the biotechnology company’s stock, valued at approximately $2,212,000. State of New Jersey Common Pension Fund D owned 0.09% of ADMA Biologics as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter worth about $29,000. EntryPoint Capital LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at approximately $31,000. Simplicity Wealth LLC bought a new stake in ADMA Biologics during the 1st quarter valued at $68,000. Oxford Asset Management LLP acquired a new position in ADMA Biologics during the 4th quarter worth $83,000. Finally, CWM LLC grew its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ADMA has been the topic of a number of recent analyst reports. Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. HC Wainwright upped their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.50.

View Our Latest Report on ADMA Biologics

Insider Buying and Selling

In related news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the completion of the transaction, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the transaction, the chief operating officer now directly owns 449,088 shares in the company, valued at approximately $7,589,587.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 in the last three months. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.74 on Friday. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $19.92. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a 50-day moving average of $15.63 and a two-hundred day moving average of $10.83. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of -987.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. As a group, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

ADMA Biologics Company Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Recommended Stories

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA – Free Report).

Receive News & Ratings for ADMA Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 20, 2024
Johnson & Johnson (NYSE:JNJ) Shares Sold by HBK Sorce Advisory LLC

[ad_1]

HBK Sorce Advisory LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% in the second quarter, HoldingsChannel reports. The firm owned 53,703 shares of the company’s stock after selling 2,517 shares during the period. HBK Sorce Advisory LLC’s holdings in Johnson & Johnson were worth $7,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Gilbert & Cook Inc. raised its stake in Johnson & Johnson by 3.3% in the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after purchasing an additional 288 shares during the last quarter. 9258 Wealth Management LLC boosted its position in Johnson & Johnson by 2.1% during the fourth quarter. 9258 Wealth Management LLC now owns 22,034 shares of the company’s stock worth $3,454,000 after acquiring an additional 443 shares during the last quarter. Gryphon Financial Partners LLC raised its holdings in Johnson & Johnson by 66.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 14,245 shares of the company’s stock valued at $2,244,000 after acquiring an additional 5,680 shares during the last quarter. Wade G W & Inc. lifted its stake in Johnson & Johnson by 0.6% in the 4th quarter. Wade G W & Inc. now owns 217,026 shares of the company’s stock worth $34,017,000 after purchasing an additional 1,332 shares in the last quarter. Finally, Inceptionr LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $404,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on JNJ shares. Sanford C. Bernstein lifted their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research note on Tuesday, July 30th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Monday, September 9th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Read Our Latest Stock Analysis on JNJ

Johnson & Johnson Stock Up 0.5 %

Shares of JNJ opened at $165.52 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $398.45 billion, a PE ratio of 10.32, a P/E/G ratio of 2.71 and a beta of 0.53. The company’s 50-day simple moving average is $159.55 and its 200-day simple moving average is $153.99. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the company posted $2.80 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 15, 2024
Bank of New York Mellon Corp Increases Position in Silk Road Medical, Inc (NASDAQ:SILK)

[ad_1]

Bank of New York Mellon Corp lifted its stake in Silk Road Medical, Inc (NASDAQ:SILK – Free Report) by 19.8% in the 2nd quarter, Holdings Channel reports. The firm owned 138,529 shares of the company’s stock after purchasing an additional 22,866 shares during the quarter. Bank of New York Mellon Corp’s holdings in Silk Road Medical were worth $3,746,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SILK. PNC Financial Services Group Inc. lifted its position in shares of Silk Road Medical by 1,293.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,523 shares of the company’s stock valued at $31,000 after acquiring an additional 2,342 shares during the period. Quest Partners LLC acquired a new position in Silk Road Medical during the fourth quarter worth $62,000. SG Americas Securities LLC purchased a new stake in Silk Road Medical during the first quarter worth $109,000. State Board of Administration of Florida Retirement System grew its holdings in Silk Road Medical by 9.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,065 shares of the company’s stock valued at $221,000 after purchasing an additional 1,090 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in Silk Road Medical in the first quarter valued at $249,000.

Insider Buying and Selling

In other Silk Road Medical news, EVP Kevin M. Klemz sold 2,268 shares of Silk Road Medical stock in a transaction on Monday, August 19th. The shares were sold at an average price of $27.10, for a total value of $61,462.80. Following the transaction, the executive vice president now owns 162,926 shares in the company, valued at approximately $4,415,294.60. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SILK. Argus downgraded Silk Road Medical from a “buy” rating to a “sell” rating in a research note on Thursday, July 11th. Lake Street Capital restated a “hold” rating and set a $27.50 target price (down previously from $28.00) on shares of Silk Road Medical in a research report on Tuesday, June 18th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $27.50 price target (up from $23.00) on shares of Silk Road Medical in a research report on Wednesday, July 17th. Two analysts have rated the stock with a sell rating and seven have issued a hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $20.29.

Get Our Latest Analysis on SILK

Silk Road Medical Trading Up 0.8 %

Shares of Silk Road Medical stock opened at $27.50 on Friday. The firm has a market cap of $1.08 billion, a PE ratio of -20.07 and a beta of 1.53. The company has a quick ratio of 6.69, a current ratio of 7.63 and a debt-to-equity ratio of 0.49. Silk Road Medical, Inc has a fifty-two week low of $6.08 and a fifty-two week high of $27.50. The business’s fifty day moving average is $27.09 and its two-hundred day moving average is $22.71.

Silk Road Medical (NASDAQ:SILK – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Silk Road Medical had a negative return on equity of 37.30% and a negative net margin of 29.53%. The business had revenue of $51.20 million during the quarter, compared to analyst estimates of $49.74 million. During the same period in the previous year, the business posted ($0.35) earnings per share. The firm’s quarterly revenue was up 13.0% on a year-over-year basis. Analysts anticipate that Silk Road Medical, Inc will post -1.45 earnings per share for the current year.

About Silk Road Medical

(Free Report)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.

Featured Stories

Want to see what other hedge funds are holding SILK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silk Road Medical, Inc (NASDAQ:SILK – Free Report).

Receive News & Ratings for Silk Road Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Silk Road Medical and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

September 15, 2024